ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

ClinicalTrials.gov ID: NCT06100276

Public ClinicalTrials.gov record NCT06100276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).

Study identification

NCT ID
NCT06100276
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
UniQure Biopharma B.V.
Industry
Enrollment
20 participants

Conditions and interventions

Interventions

  • AMT-162 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2024
Primary completion
Sep 29, 2026
Completion
Jun 29, 2031
Last update posted
Oct 21, 2025

2024 – 2031

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Barrow Neurological Institute Phoenix Arizona 85013
University of California Irvine Irvine California 92697
California Pacific Medical Center San Francisco California 94109
Mayo Clinic Florida Jacksonville Florida 32224
Winship Cancer Institute of Emory University Atlanta Georgia 30322
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
University of Kansas Medical Center Fairway Kansas 66205
Massachusetts General Hospital, Sean M. Healey and AMG Center for ALS Research Boston Massachusetts 02114
Mayo Clinic Rochester Rochester Minnesota 55905
Columbia University Irving Medical Center New York New York 10032
University of Pennsylvania School of Medicine Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06100276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 21, 2025 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06100276 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →